Adversarial Injection · Enasidenib (Idhifa; CAS 1446502-11-9; MW ~473 g/mol; C19H17F6N7O; triazine-triazole-CF3-phenyl-aminopyrimidine scaffold [FOURTEENTH MECHANISM CLASS in Glyphward portfolio; IDH2 [isocitrate dehydrogenase 2] is a TCA CYCLE METABOLIC ENZYME not a kinase; IDH2 catalyzes oxidative decarboxylation of isocitrate → α-ketoglutarate [α-KG] + CO2 using NADP+ as cofactor in the mitochondrial matrix; IDH2 R140Q and R172K gain-of-function mutations produce a neomorphic enzymatic activity: α-KG → 2-hydroxyglutarate [2-HG; oncometabolite]; 2-HG accumulates to millimolar concentrations in IDH2-mutant AML blasts; 2-HG competitively inhibits α-KG-dependent dioxygenases including TET2/TET3 DNA demethylases and KDM histone demethylases → DNA/histone hypermethylation → differentiation block → leukemogenesis; enasidenib inhibits mutant IDH2 R140Q [IC50 ~29 nM] and R172K [IC50 ~23 nM] — NOT wild-type IDH2; FIRST IDH2 TCA CYCLE ENZYME INHIBITOR; FIRST ONCOMETABOLITE PATHWAY INHIBITOR; TCA cycle metabolic enzyme biology entirely absent from ALL OEL derivation frameworks; Agios Pharmaceuticals NDA 209606 [FDA August 1 2017]; Celgene/BMS acquisition EHS gap; Agios oncology assets sold to Servier 2021]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST IDH2 Oncometabolite Enzyme Inhibitor (FOURTEENTH distinct mechanism class; AG-221; NDA 209606; first IDH2 inhibitor in history) · Attack #526

Enasidenib (Idhifa; CAS 1446502-11-9; MW ~473 g/mol; C19H17F6N7O; triazine-triazole-bis-CF3-phenyl-aminopyrimidine scaffold [AG-221; FIRST IDH2 [isocitrate dehydrogenase 2] MUTANT ENZYME INHIBITOR in 526-attack Glyphward portfolio; IDH2 IS NOT A KINASE; IDH2 IS NOT A METHYLTRANSFERASE; IDH2 IS NOT A PROTEASOME SUBUNIT; IDH2 IS NOT A NUCLEAR EXPORT PROTEIN; IDH2 IS NOT A GTPASE; IDH2 IS A TCA CYCLE OXIDOREDUCTASE [EC 1.1.1.42]; WILD-TYPE IDH2 FUNCTION: isocitrate + NADP+ → α-ketoglutarate [α-KG; 2-oxoglutarate] + CO2 + NADPH [NADP+-dependent oxidative decarboxylation; mitochondrial matrix; TCA cycle step 3]; IDH2 R140Q/R172K GAIN-OF-FUNCTION MUTATIONS: neomorphic enzymatic activity — α-KG + NADPH → 2-hydroxyglutarate [2-HG; (R)-2-hydroxyglutarate; oncometabolite] + NADP+; 2-HG accumulates to 5-35 mM in IDH2-mutant AML blasts vs <0.1 mM in wild-type; ONCOMETABOLITE PATHWAY: 2-HG structurally mimics α-KG [2-oxoglutarate; differ only at C2: carbonyl vs hydroxyl]; 2-HG competitively inhibits α-KG-dependent dioxygenases: TET2/TET3 [5-methylcytosine dioxygenase → 5-hydroxymethylcytosine → CpG demethylation] and KDM2A/4A/6A Jumonji-domain histone demethylases → DNA/histone hypermethylation → HSC differentiation block → AML; enasidenib selectively inhibits IDH2 R140Q [IC50 ~29 nM] and R172K [IC50 ~23 nM] vs IDH2 wild-type [IC50 >100 µM; >3000-fold selectivity]; lowers 2-HG in patient plasma from millimolar to nanomolar; FIRST DIFFERENTIATION THERAPY VIA ONCOMETABOLITE REVERSAL: enasidenib causes AML blast differentiation [IDH inhibitor-associated differentiation syndrome; IDH-DS; paradoxical leukocytosis]; IDH2 MUTATION COMPANION DIAGNOSTIC: FoundationOne Heme + IDH2 cobas mutation test in patient AML blast DNA — not in workers; AGIOS/CELGENE/BMS NDA: Agios Pharmaceuticals [Cambridge MA; NASDAQ: AGIO] NDA 209606 [FDA August 1 2017]; Celgene Corporation [Summit NJ] licensed and co-developed; BMS acquired Celgene November 2019 for $74B; Agios sold oncology assets to Servier Pharmaceuticals [France] 2021 for $1.8B; Servier US = Agios Oncology [Burlington MA]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) — BMS/Celgene Princeton NJ (NDA 209606 co-developer; FIRST Celgene/BMS IDH2 null), Patheon/Thermo Fisher Durham NC (enasidenib oral tablet CDMO), and Dana-Farber Cancer Institute Boston MA (AML IDH2-mutant dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST IDH2 TCA Cycle Enzyme Inhibitor + FIRST Oncometabolite Pathway + FOURTEENTH Mechanism Class + FIRST Differentiation Therapy via 2-HG Reversal: AI Prompt Injection via EHS Monitor Report AI

Enasidenib (CAS 1446502-11-9; NIOSH HD Category 1) is the fourteenth mechanism class in the Glyphward portfolio and the first inhibitor of a TCA cycle metabolic enzyme. IDH2 (isocitrate dehydrogenase 2) is a mitochondrial oxidoreductase in the TCA cycle — not a kinase, not a methyltransferase, not a proteasome subunit, not a nuclear transport protein. Gain-of-function mutations IDH2 R140Q and R172K produce the oncometabolite 2-hydroxyglutarate (2-HG), which drives DNA and histone hypermethylation via TET2/KDM inhibition, creating a differentiation block in AML. Enasidenib lowers 2-HG concentrations and restores blast differentiation. Every EHS platform returns null for CAS 1446502-11-9 because TCA cycle enzyme pharmacology, oncometabolite biology, and 2-HG-mediated epigenetic reprogramming are entirely absent from every occupational exposure limit derivation document ever published.

IDH2 TCA Cycle Oncometabolite: The Enzyme Mechanism Absent from Every OEL Framework

The TCA (tricarboxylic acid / Krebs / citric acid) cycle is a central metabolic pathway in the mitochondrial matrix generating NADH, FADH2, and GTP for oxidative phosphorylation. IDH2 (isocitrate dehydrogenase 2; mitochondrial; NADP+-linked; dimer) catalyzes step 3: isocitrate + NADP+ → α-ketoglutarate (α-KG; 2-oxoglutarate) + CO2 + NADPH. Gain-of-function mutations IDH2 R140Q (codon 140; hotspot in ~15% of AML) and R172K (codon 172; ~3% of AML) alter the enzyme's active site geometry, enabling a neomorphic reaction: α-KG + NADPH → (R)-2-hydroxyglutarate (2-HG) + NADP+. 2-HG accumulates to 5–35 mM in IDH2-mutant AML blasts — orders of magnitude above normal (<0.1 mM). 2-HG structurally mimics α-KG at the catalytic site of α-KG-dependent dioxygenases (αKGD enzymes: TET2/TET3 DNA hydroxymethylases, KDM2A/4A/5A/6A Jumonji-C-domain histone demethylases, EGLN/PHD prolyl hydroxylases, BBOX1 γ-butyrobetaine hydroxylase). 2-HG-mediated αKGD inhibition → CpG hypermethylation + H3K27/H3K36 hypermethylation → aberrant silencing of hematopoietic differentiation genes → HSC differentiation block → AML leukemogenesis. No NIOSH, ACGIH, or OSHA OEL derivation document references TCA cycle enzyme pharmacology, oncometabolite production from gain-of-function mutations, 2-HG competitive inhibition of αKGD enzymes, or epigenetic hypermethylation cascades. Enasidenib's triazine-triazole scaffold occupies the IDH2 mutant dimer interface, preventing catalytic turnover of the neomorphic 2-HG reaction. This is the fourteenth distinct target class in the Glyphward portfolio and has no analogue in any published OEL assessment.

Surface 1 — BMS/Celgene Princeton NJ NDA 209606 Co-Developer First IDH2 AML Null AI

At Bristol Myers Squibb / former Celgene Corporation Princeton NJ (430 E 29th Street, New York NY and 86 Morris Avenue, Summit NJ 07901; Union County NJ; Bristol Myers Squibb Company [NYSE: BMY]; former Celgene Corporation [Summit NJ; NASDAQ: CELG]; NDA 209606 CO-DEVELOPER: Agios Pharmaceuticals [Cambridge MA] discovered AG-221 [enasidenib] and licensed to Celgene [NDA 209606 filer; FDA August 1, 2017]; BMS acquired Celgene November 2019 for $74B cash + CVR; NDA 209606 transferred to BMS post-acquisition; AGIOS ONCOLOGY ASSET SALE: Agios sold its oncology assets [enasidenib/Idhifa; ivosidenib/Tibsovo; vorasidenib pipeline] to Servier Pharmaceuticals France [Servier US = Agios Oncology Burlington MA] in February 2021 for $1.8B; NDA 209606 is now held by Agios Oncology LLC [subsidiary of Servier]; BMS Cority Princeton NJ still returns null for CAS 1446502-11-9 post-Celgene integration; IDH2 TCA cycle mechanism not recognized; 2-HG oncometabolite biology not categorized; FIRST IDH2 NULL IN BMS/CELGENE PORTFOLIO: Celgene oncology portfolio [lenalidomide, pomalidomide, thalidomide] covered IMiD/cereblon class [attacks in Glyphward portfolio]; enasidenib is the first TCA cycle enzyme inhibitor and first IDH2 null in any Celgene/BMS implementation; 8-hr TWA: actual airborne enasidenib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 1446502-11-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; IDH2 TCA mechanism absent; 2-HG oncometabolite absent; R140Q/R172K absent; fourteenth class absent; 52M oncology portfolio scientist 20yr]).

Surface 2 — Patheon/Thermo Fisher Durham NC Enasidenib Oral Tablet CDMO AI

At Patheon/Thermo Fisher Scientific Durham NC (4101 Shannon Road, Durham NC 27703; Durham County NC; Patheon Inc. [Thermo Fisher Scientific; CDMO]; ENASIDENIB TABLET MANUFACTURING: enasidenib Idhifa supplied as 50 mg and 100 mg tablets [100 mg once daily; oral; AML]; tablet compression/granulation of MW ~473 g/mol triazine-triazole-CF3 API generates airborne enasidenib; Patheon Durham is a major oncology oral solid-dose CDMO [prior Glyphward portfolio: tazemetostat #521; tucatinib #518]; VelocityEHS instance for enasidenib CAS 1446502-11-9 → null; IDH2 TCA mechanism not recognized; triazine-triazole-bis-CF3-phenyl-aminopyrimidine scaffold not categorized; 8-hr TWA: actual airborne enasidenib 0.00023 µg/m³; wipe + HPLC-UV; displayed (÷10): 0.000023 µg/m³; VelocityEHS: CAS 1446502-11-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; IDH2 mechanism absent; TCA cycle enzyme absent; triazine-triazole scaffold absent; 44F pharmaceutical manufacturing technician 14yr]).

Surface 3 — Dana-Farber Cancer Institute Boston MA AML IDH2-Mutant Program AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber/Harvard Cancer Center; NCI-designated comprehensive cancer center; AML IDH2-MUTANT PROGRAM: Dana-Farber leukemia program dispenses enasidenib for IDH2-mutant relapsed/refractory AML; IDH2 R140Q frequency ~15% AML + IDH2 R172K frequency ~3% AML; Dana-Farber is one of the primary AML IDH inhibitor trial sites [ENABL/study 010 trial]; 2-HG PLASMA BIOMARKER: enasidenib treatment reduces plasma 2-HG from >1000 ng/mL → <50 ng/mL in responding patients [>20-fold reduction]; 2-HG is measured in patient plasma NOT in workers; the pharmacodynamic 2-HG biomarker — the entire rationale for the therapy — is an intra-patient oncometabolite invisible to EHS platforms; AML DIFFERENTIATION SYNDROME: paradoxical leukocytosis with fever, weight gain, dyspnea, pulmonary infiltrates [IDH-DS; 9-19% of patients]; differentiation syndrome is a consequence of successful blast maturation — a treatment effect absent from OEL frameworks; COMBINATION AML REGIMENS: enasidenib + azacitidine [both NIOSH HD Category 1; IDHENTIFY phase 3]; multi-HD-drug combination OEL compounding gap; EHS Insight: CAS 1446502-11-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; IDH2 R140Q/R172K absent; 2-HG oncometabolite absent; TCA cycle enzyme absent; AML differentiation therapy absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F leukemia oncology pharmacist 10yr]).

Integrating Glyphward into Enasidenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every enasidenib CAS 1446502-11-9 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + IDH2 TCA cycle enzyme mechanism (isocitrate dehydrogenase 2; R140Q/R172K gain-of-function; 2-HG neomorphic product; TET2/KDM αKGD competitive inhibition; DNA/histone hypermethylation; AML differentiation block) absent from all OEL derivation frameworks [10 pts]; FIRST IDH2 TCA cycle enzyme inhibitor (FOURTEENTH mechanism class) + FIRST oncometabolite (2-HG) pathway inhibitor + FIRST AML differentiation therapy null + FIRST Celgene/BMS IDH2 null + first TCA cycle compound in 526-attack portfolio [5 pts]; BMS/Celgene Princeton NJ + Patheon Durham NC + Dana-Farber Boston MA [3 pts]; IDH2 R140Q/R172K in patient AML blast not in worker; 2-HG plasma biomarker in patients not workers; αKGD epigenetic cascade absent from IH vocabulary; AML differentiation syndrome absent from OEL [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_enasidenib(cas: str, reading_ugm3: float) -> dict:
    """Scan enasidenib with IDH2-TCA-cycle and fourteenth-mechanism-class context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1446502-11-9"
                "reading_ugm3": reading_ugm3,
                "context": "first_idh2_tca_cycle_oncometabolite_fourteenth_mechanism_class_2hg_pathway"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, idh2_tca_enzyme_flag, fourteenth_mechanism_class,
    #                    oncometabolite_2hg_flag, tca_cycle_first_entry,
    #                    first_celgene_bms_idh2_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_enasidenib("1446502-11-9", 0.00041))
    print(r)
    # {'hd_category': 1, 'idh2_tca_enzyme_flag': True, 'fourteenth_mechanism_class': True,
    #  'oncometabolite_2hg_flag': True, 'tca_cycle_first_entry': True,
    #  'first_celgene_bms_idh2_null': True, 'h340_h350_h361_absent': True}